Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Sanofi will take the lead co-commercialization role for ... give this vaccine candidate the highest probability of success ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

As RSV season ramps up, the American Lung Association is partnering with Sanofi to help educate parents and expectant ... infants and some young children at increased risk, and an RSV vaccine received ...

While the inquiry gets most things right, as vaccine experts, we argue the government response should be broadened in three ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

The pharmaceutical company reported third-quarter earnings and sales that beat analysts’ expectations, boosted by ...

its RSV antibody for infants. Announcing earnings Friday, the French pharmaceutical company said Beyfortus sales were 645 million euros, or about $700 million. Overall, Sanofi’s vaccines unit ...

GSK, Sanofi, CSL nab $72M in BARDA funding to boost bird flu vaccine supply In Merck’s infant RSV study, clesrovimab managed to cut RSV-related hospitalizations and RSV-related lower respiratory ...

AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

scoring FDA approval for an adult RSV vaccine in May. In the RSV market for infants, AstraZeneca and Sanofi’s Beyfortus leads the way. It achieved sales of 547 million euros ($592 million ...

Sanofi has added to its vaccine pipeline with an agreement ... It will highlight vaccines for pneumococcal disease, meningitis, respiratory syncytial virus (RSV), influenza, and chlamydia.